{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-25-000053","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.096657+00:00","generated_at":"2026-05-24T16:09:38.427040+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GRI Bio reports FY2024 net loss of $8.2M; cash runway into Q2 2025","bullets":["Net loss of $8.2M for FY2024; R&D spend increased 19% to $3.8M; G&A fell 45% to $4.5M.","Cash and equivalents of $5.0M at Dec 31, 2024; runway only into Q2 2025 (through interim data).","Phase 2a interim data for GRI-0621 in IPF expected Q2 2025; topline results Q3 2025.","European patent granted for GRI-0803 and library of 500+ proprietary NKT cell modulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-25-000053","json":"https://secwatch.observer/filing/0001824293-25-000053.json","markdown":"https://secwatch.observer/filing/0001824293-25-000053.md","text":"https://secwatch.observer/filing/0001824293-25-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/0001824293-25-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/val-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T16:09:38.427040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}